Understanding cognitive disorders in newly diagnosed epilepsy patients
Prevalence of Cognitive Disorders in Newly Diagnosed Epilepsy
This study looks at how common thinking problems are in adults who have just been diagnosed with epilepsy, before they start any medication, to help improve their care.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 16 Years and up |
| Sex | All |
| Sponsor | Central Hospital, Nancy, France Academic / other |
| Locations | 1 site (Nancy) |
| Trial ID | NCT04727931 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the prevalence of cognitive impairments in adults who have recently been diagnosed with epilepsy, prior to starting any antiepileptic drug treatment. It will involve neuropsychological assessments and questionnaires to evaluate cognitive performance and its relationship with various factors such as type of epilepsy, age, and treatment history. The study will also follow patients over time to observe changes in cognitive profiles, highlighting the complex interplay between cognitive function and epilepsy. By identifying these impairments early, the study seeks to inform better management strategies for affected individuals.
Who should consider this trial
Good fit: Ideal candidates include individuals aged 16 and over who have recently been diagnosed with epilepsy and have not yet started antiepileptic treatment.
Not a fit: Patients with progressive brain injuries or those who regularly use psychoactive substances may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of cognitive impairments in patients with newly diagnosed epilepsy.
How similar studies have performed: Other studies have indicated a significant prevalence of cognitive impairments in epilepsy, suggesting that this approach is relevant and may yield valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria (patients): * Individuals who have received full information about the organization of the research and have not refused to participate and to use their data. * Person aged 16 and over * For minor patients: the non-opposition of the parental authority holders * Newly diagnosed epileptic patient who had never taken antiepileptic drugs. Inclusion Criteria (normal controls): * Individuals who have received full information about the organization of the research and have not refused to participate and to use their data. * For minor participants: the non-opposition of the parental authority holders * Person aged 16 and over. Exclusion Criteria (patients): * Person of full age who are subject to a legal protection measure or who are unable to express their consent * Person with a progressive brain injury * Person who regularly use psychoactive substances (cannabis, alcohol, etc.) * Patients who started an antiepileptic treatment before the neuropsychological assessment. Exclusion Criteria (normal controls): * Persons of full age who are subject to a legal protection measure or who are unable to express their consent * Person with a neurological (traumatic brain injury, stroke, etc.) and/or psychiatric (mental illness, depression, etc.) history. * People who regularly use psychoactive substances (cannabis, alcohol, etc.).
Where this trial is running
Nancy
- Department of neurology - Hospital of Nancy — Nancy, France (Recruiting)
Study contacts
- Principal investigator: Louis Maillard, Pr — Professor of neurology
- Study coordinator: Natacha Forthoffer
- Email: n.forthoffer@chru-nancy.fr
- Phone: 03.83.85.20.77
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.